JUVE Patent

About Bas Berghuis von Woortman

Bas is the national head of the IP practice in The Netherlands. For almost 25 years, Bas’ practice covers the full range of intellectual property activities, with a focus on patent and technology based litigation.

Bas has a particular expertise in the life sciences sector, handling matters regarding medical devices, pharmaceuticals and biotech, and in the TMT sector, acting in matters regarding electronics, telecoms and software. Described by clients as “business-oriented, responsive and proactive“, Bas acts before national and international courts, as well as the Dutch and European Patent Offices. He has been involved in all aspects of litigation, as well as other IP related issues such as licensing, patent prosecution strategy, negotiation of research and development agreements and issues relating to trade secrets and the protection of know-how.

Bas is Board Member of EPLAW, the European Patent Lawyer’s Association. He is recommended by all leading directories including Chambers, Legal 500, IAM Patent and IP Stars for many years. Client’s praise the value of his advice and enthuse: “He’s extremely thorough. He knows every detail, has a way of putting things into perspective and he manages his team very well.”

Awards

• Ranked “Gold Tier” for Patent Litigation; and Patent Transactions by IAM Patent 1000: The World’s Leading Patent Professionals (2020)
• “Recommended” for Patent Litigation by Juve Patent 2021
• “Patent Star’” – Managing IP Stars 2021
• “Recommended” for Intellectual Property by Chambers and Partners Netherlands 2020
• Recognised “Leading Individual” by Legal500 Netherlands for Intellectual Property: Patents; and Healthcare and Life Sciences

Publications

• Gemeenten aansprakelijk voor schade openbaarmaking ritgegevens
  https://www.simmons-simmons.com/en/publications/ckk5e52yq1a550945fu0dqy4u/gemeenten-aansprakelijk-voor-schade-openbaarmaking-ritgegevens
• Pan-Europees dispuut: Xiaomi maakt geen inbreuk op Sisvel octrooi
  https://www.simmons-simmons.com/en/publications/ckhm9ar6q7wvc0944erq64oge/pan-europees-dispuut-xiaomi-maakt-geen-inbreuk-op-sisvel-octrooi
• Mylan mag geen inbreuk maken op ABC van Novartis voor geneesmiddel
  https://www.simmons-simmons.com/en/publications/ckgj3p28018bh0944rgbdcte6/mylan-mag-geen-inbreuk-maken-op-abc-van-novartis-voor-geneesmiddel
• On-line zittingen; de gang van zaken bij pleidooi in octrooizaken
  https://www.simmons-simmons.com/en/publications/ckfz2zyifvkif0943j3j6znj7/on-line-zittingen-de-gang-van-zaken-bij-pleidooi-in-octrooizaken
• 1 september 2020: Invoering indicatietarieven in octrooizaken
  https://www.simmons-simmons.com/en/publications/ckfe8hcaqogpm092680rn3try/1-september-2020-invoering-indicatietarieven-in-octrooizaken